Guo X, Liu X, Guo C, Miao Q, Cheng X, Hong X
Thorac Cancer. 2025; 16(4):e70018.
PMID: 39980151
PMC: 11842451.
DOI: 10.1111/1759-7714.70018.
Zhang Q, Duan J, Zhang Y, Yang L, Li D
Syst Rev. 2025; 14(1):24.
PMID: 39856765
PMC: 11760710.
DOI: 10.1186/s13643-025-02767-6.
Chen Y, Qi F, Sun C, Jiang P, Xue X, Yang X
Ther Adv Med Oncol. 2025; 17():17588359241312501.
PMID: 39781239
PMC: 11707791.
DOI: 10.1177/17588359241312501.
Yu X, Huang C, Du L, Wang C, Yang Y, Yu X
EClinicalMedicine. 2024; 79:102997.
PMID: 39720604
PMC: 11667015.
DOI: 10.1016/j.eclinm.2024.102997.
Li B, Gu Y, Zhao W, Li Z, Guo W, Lu X
Clin Transl Oncol. 2024; .
PMID: 39251495
DOI: 10.1007/s12094-024-03704-0.
Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review.
Zhou S, Shen C, Wang Y, Zhao Z, Che G
J Thorac Dis. 2024; 16(7):4742-4755.
PMID: 39144303
PMC: 11320285.
DOI: 10.21037/jtd-24-265.
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.
Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D
J Immunother Cancer. 2024; 12(6).
PMID: 38908857
PMC: 11328648.
DOI: 10.1136/jitc-2024-009165.
A case report of cStage IIIB squamous cell lung carcinoma completely resected after downstaging with neoadjuvant therapy.
Li J, Zu P, Jakopovic M, Legras A, Saji H, Onodera K
J Thorac Dis. 2024; 16(5):3503-3511.
PMID: 38883681
PMC: 11170368.
DOI: 10.21037/jtd-24-522.
Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis.
Ye L, Liu Y, Xiang X, Wang Z, Peng W, Wei X
Heliyon. 2024; 10(11):e31549.
PMID: 38828349
PMC: 11140712.
DOI: 10.1016/j.heliyon.2024.e31549.
Effective neoadjuvant immunotherapy and chemotherapy in stage IIIA adenosquamous carcinoma of the lung with a complete response and surgical success: A case report.
Song C, Nie Y, Liu T, Peng X, Liu J, Zhou Z
Oncol Lett. 2024; 28(1):314.
PMID: 38807664
PMC: 11130605.
DOI: 10.3892/ol.2024.14448.
A Review of the Current Approach and Treatment Landscape for Stage III Non-Small Cell Lung Cancer.
Sridhar A, Khan H, Yohannan B, Chan K, Kataria N, Jafri S
J Clin Med. 2024; 13(9).
PMID: 38731161
PMC: 11084624.
DOI: 10.3390/jcm13092633.
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.
Bogatsa E, Lazaridis G, Stivanaki C, Timotheadou E
Cancers (Basel). 2024; 16(9).
PMID: 38730571
PMC: 11083960.
DOI: 10.3390/cancers16091619.
Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure?.
Salter A, Das M
Transl Lung Cancer Res. 2024; 13(3):673-677.
PMID: 38601451
PMC: 11002516.
DOI: 10.21037/tlcr-23-735.
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives.
Bertolaccini L, De Giglio A, Gariazzo E, Metro G
Oncol Ther. 2024; 12(2):207-215.
PMID: 38483781
PMC: 11187012.
DOI: 10.1007/s40487-024-00267-6.
[Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
Wang H, Han Y
Zhongguo Fei Ai Za Zhi. 2023; 26(11):822-832.
PMID: 38061884
PMC: 10714043.
DOI: 10.3779/j.issn.1009-3419.2023.102.40.
Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
Yin C, Hu B, Yang X, Kou L, Tian B, Wang C
World J Surg Oncol. 2023; 21(1):304.
PMID: 37749594
PMC: 10521519.
DOI: 10.1186/s12957-023-03194-4.
